<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 /home/abel/Downloads/grobid-0.5.6/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2014-07-26">Available online 26 July 2014</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sheng-Fan</forename><surname>Wang</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Medical Laboratory Science and Biotechnology</orgName>
								<orgName type="institution">Kaohsiung Medical University</orgName>
								<address>
									<settlement>Kaohsiung</settlement>
									<country key="TW">Taiwan</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Institute of Biomedical Sciences</orgName>
								<orgName type="institution">Academia Sinica</orgName>
								<address>
									<settlement>Taipei</settlement>
									<country key="TW">Taiwan</country>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<orgName type="department">Center for Infectious Disease and Cancer Research</orgName>
								<orgName type="institution">Kaohsiung Medical University</orgName>
								<address>
									<settlement>Kaohsiung</settlement>
									<country key="TW">Taiwan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sung-Pin</forename><surname>Tseng</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Medical Laboratory Science and Biotechnology</orgName>
								<orgName type="institution">Kaohsiung Medical University</orgName>
								<address>
									<settlement>Kaohsiung</settlement>
									<country key="TW">Taiwan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Chia-Hung</forename><surname>Yen</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Graduate Institute of Natural Products</orgName>
								<orgName type="department" key="dep2">College of Pharmacy</orgName>
								<orgName type="institution">Kaohsiung Medical University</orgName>
								<address>
									<settlement>Kaohsiung</settlement>
									<country key="TW">Taiwan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jyh-Yuan</forename><surname>Yang</surname></persName>
							<affiliation key="aff3">
								<orgName type="department" key="dep1">Center for Research</orgName>
								<orgName type="department" key="dep2">Diagnostics and Vaccine Development</orgName>
								<orgName type="department" key="dep3">Centers for Disease Control</orgName>
								<address>
									<settlement>Taipei</settlement>
									<country key="TW">Taiwan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ching-Han</forename><surname>Tsao</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Institute of Biomedical Sciences</orgName>
								<orgName type="institution">Academia Sinica</orgName>
								<address>
									<settlement>Taipei</settlement>
									<country key="TW">Taiwan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Chun-Wei</forename><surname>Shen</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Office of Occupational Safety and Health</orgName>
								<orgName type="institution">Kaohsiung Municipal Ta-Tung Hospital</orgName>
								<address>
									<settlement>Kaohsiung</settlement>
									<country key="TW">Taiwan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kuan-Hsuan</forename><surname>Chen</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Center for Infectious Disease and Cancer Research</orgName>
								<orgName type="institution">Kaohsiung Medical University</orgName>
								<address>
									<settlement>Kaohsiung</settlement>
									<country key="TW">Taiwan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Fu-Tong</forename><surname>Liu</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Institute of Biomedical Sciences</orgName>
								<orgName type="institution">Academia Sinica</orgName>
								<address>
									<settlement>Taipei</settlement>
									<country key="TW">Taiwan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Wu-Tse</forename><surname>Liu</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Department of Biotechnology and Laboratory Science in Medicine</orgName>
								<orgName type="institution">National Yang-Ming University</orgName>
								<address>
									<settlement>Taipei</settlement>
									<country key="TW">Taiwan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yi-Ming</forename><forename type="middle">Arthur</forename><surname>Chen</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Center for Infectious Disease and Cancer Research</orgName>
								<orgName type="institution">Kaohsiung Medical University</orgName>
								<address>
									<settlement>Kaohsiung</settlement>
									<country key="TW">Taiwan</country>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="department" key="dep1">Department of Microbiology</orgName>
								<orgName type="department" key="dep2">College of Medicine</orgName>
								<orgName type="institution">Kaohsiung Medical University</orgName>
								<address>
									<settlement>Kaohsiung</settlement>
									<country key="TW">Taiwan</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jason</forename><forename type="middle">C</forename><surname>Huang</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Department of Biotechnology and Laboratory Science in Medicine</orgName>
								<orgName type="institution">National Yang-Ming University</orgName>
								<address>
									<settlement>Taipei</settlement>
									<country key="TW">Taiwan</country>
								</address>
							</affiliation>
							<affiliation key="aff8">
								<orgName type="laboratory">AIDS Prevention and Research Center</orgName>
								<orgName type="institution">National Yang-Ming University</orgName>
								<address>
									<settlement>Taipei</settlement>
									<country key="TW">Taiwan</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2014-07-26">Available online 26 July 2014</date>
						</imprint>
					</monogr>
					<idno type="DOI">10.1016/j.bbrc.2014.07.090</idno>
					<note type="submission">Article history: Received 5 July 2014</note>
					<note>a r t i c l e i n f o</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>

		<encodingDesc>
			<appInfo>
				<application version="0.5.6" ident="GROBID" when="2020-03-16T22:29+0000">
					<ref target="https://github.com/kermitt2/grobid">GROBID - A machine learning software for extracting information from scholarly documents</ref>
				</application>
			</appInfo>
		</encodingDesc>		<profileDesc>
			<textClass>
				<keywords>Antibody-dependent enhancement Anti-spike antibody Fc receptors HL-CZ SARS-CoV</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>a b s t r a c t</head><p>The severe acute respiratory syndrome coronavirus (SARS-CoV) still carries the potential for reemergence, therefore efforts are being made to create a vaccine as a prophylactic strategy for control and prevention. Antibody-dependent enhancement (ADE) is a mechanism through which dengue viruses, feline coronaviruses, and HIV viruses take advantage of anti-viral humoral immune responses to infect host target cells. Here we describe our observations of SARS-CoV using ADE to enhance the infectivity of a HL-CZ human promonocyte cell line. Quantitative-PCR and immunofluorescence staining results indicate that SARS-CoV is capable of replication in HL-CZ cells, and of displaying virus-induced cytopathic effects and increased levels of TNF-a, IL-4 and IL-6 two days post-infection. According to flow cytometry data, the HL-CZ cells also expressed angiotensin converting enzyme 2 (ACE2, a SARS-CoV receptor) and higher levels of the FccRII receptor. We found that higher concentrations of anti-sera against SARS-CoV neutralized SARS-CoV infection, while highly diluted anti-sera significantly increased SARS-CoV infection and induced higher levels of apoptosis. Results from infectivity assays indicate that SARS-CoV ADE is primarily mediated by diluted antibodies against envelope spike proteins rather than nucleocapsid proteins. We also generated monoclonal antibodies against SARS-CoV spike proteins and observed that most of them promoted SARS-CoV infection. Combined, our results suggest that antibodies against SARS-CoV spike proteins may trigger ADE effects. The data raise new questions regarding a potential SARS-CoV vaccine, while shedding light on mechanisms involved in SARS pathogenesis.</p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.">Introduction</head><p>Coronaviruses are enveloped viruses with positive stranded, capped, and poly-adenylated RNA genomes ranging between 28 and 32 kb <ref type="bibr" target="#b0">[1]</ref>. Coronaviruses cause respiratory and enteric diseases in both humans and domesticated animals-for example, human coronaviruses 229E (HCoV-229E) and OC43 (HCoV-OC43) are known to cause mild upper respiratory tract infections. In 2003, a new severe acute respiratory syndrome coronavirus (SARS-CoV) was discovered during an outbreak of that disease <ref type="bibr" target="#b0">[1]</ref>, which infected more than 8000 individuals and killed more than 700, with most identified cases occurring in Asia <ref type="bibr" target="#b1">[2]</ref>. Originally it was assumed that SARS-CoV is transmitted via respiratory droplets or direct contact <ref type="bibr" target="#b2">[3]</ref>. However, some researchers now suggest that it can also be spread via airborne or other unknown processes <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b2">3]</ref>.</p><p>The SARS-CoV genome consists of 28 putative open reading frames (ORFs) in 9 mRNA transcripts. <ref type="bibr">ORF1a</ref>  account for approximately two-thirds of the genome, both encode large polyproteins. The genome encodes four major structural proteins: spike (S), envelope (E), membrane (M), and nucleocapsid (N) <ref type="bibr" target="#b1">[2]</ref>. Viral surface spike glycoproteins initiate SARS-CoV entry into cells by binding to angiotensin-converting enzyme 2 (ACE2) receptors, followed by conformational changes resulting in membrane fusion and genome delivery to the cytoplasm <ref type="bibr" target="#b3">[4]</ref>. SARS-CoV S protein is a type I transmembrane protein consisting of distinct N-terminal (S1) and C-terminal (S2) domains that respectively mediate receptor binding and virus-cell fusion. S proteins are key targets for generating protective neutralizing antibodies against coronaviruses <ref type="bibr" target="#b1">[2,</ref><ref type="bibr" target="#b4">5]</ref>. Minor alterations in the S protein can affect tissue, species tropism, and coronavirus virulence. The primary function of a nucleocapsid protein is to form helical ribonucleoprotein complexes with viral RNA (vRNA) <ref type="bibr" target="#b5">[6]</ref>. In addition to comprising the core structure of the SARS-CoV virion, such complexes are involved in multiple functions such as transcription, replication, and virus packaging <ref type="bibr" target="#b1">[2,</ref><ref type="bibr" target="#b5">6]</ref>.</p><p>Several vaccine strategies under study target SARS-CoV spike genes or proteins to induce neutralizing and protective antibodies. However, a significant concern is that vaccinations against different kinds of coronaviruses have markedly different outcomes <ref type="bibr" target="#b6">[7]</ref>-for example, anti-spike antibodies offer protection against mouse hepatitis and transmissible gastroenteritis, but boost feline-coronavirus (FCoV) infections <ref type="bibr" target="#b7">[8]</ref>. An alternative virus entry process known as antibody dependent enhancement (ADE) has been observed in viruses such as dengue, yellow fever, HIV, and FCoV, among others <ref type="bibr" target="#b6">[7]</ref>. Although the ADE mechanism is not completely understood, it is generally assumed that increased virus yields are due to infections of large numbers of susceptible cells. Such increases are mediated by immunoglobulin receptors such as Fc (FcRs) or complement receptors that facilitate the uptake of virus-antibody complexes into phagocytes, resulting in enhanced target cell infections <ref type="bibr" target="#b6">[7]</ref>. However, it remains unclear whether SARS-CoV uses ADE to enhance infectivity.</p><p>We used SARS-CoV clinical isolates and pseudotyped viruses to determine whether ADE occurs during SARS-CoV infection. Our experiments involved a human promonocyte cell line, HL-CZ, that has not yet been reported for SARS-CoV infections. According to our data, HL-CZ cells express ACE2 and FcRII receptors, and can be infected by SARS-CoV. We also noted that diluted anti-sera against SARS-CoV promotes SARS-CoV infection, and that this phenomenon is significantly mediated by anti-S antibodies. Finally, only one of several monoclonal antibodies against S proteins generated for this project expressed neutralizing action; the others displayed mild-to-moderate ADE effects on HL-CZ cells.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.">Materials and methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.1.">Ethics statement</head><p>Approval for obtaining sera from SARS-CoV patients was applied for and received from the Institutional Ethics Committee of National Yang-Ming University. All procedures were conducted according to committee rules.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.2.">Cell lines, viruses and anti-sera</head><p>Five cell lines were used: HL-CZ human promonocyte isolated from a leukemia patient <ref type="bibr" target="#b8">[9]</ref>; HEK293T human kidney; Vero-E6 African Green Monkey kidney; Raji B; and THP-1 monocyte. SARS-CoV (TW1 strain, GenBank accession No. AY291451) was obtained from the Taiwan Centers for Disease Control (Taiwan CDC) <ref type="bibr" target="#b9">[10]</ref>. SARS-CoV pseudo-typed virus particles carrying the SARS-CoV S protein were generated by co-transfecting HEK293T cells with pNL-Luc-E-R-and pcDNA3-S <ref type="bibr" target="#b3">[4,</ref><ref type="bibr" target="#b10">11]</ref>. Anti-SARS CoV sera were collected from SARS-CoV-infected patients and confirmed at the Taiwan CDC labs.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.3.">Infectivity and neutralization assays</head><p>HL-CZ or Vero-E6 cells (1 Â 10 5 /well) were used in direct infection assays. SARS-CoV or pseudotyped viruses (MOI = 0.1) were incubated with cells for 2 h at 37°C in serum-free medium and washed with PBS. Following incubation, 2 ml of RPMI or DMEM medium containing 10% serum and 1X (100 IU penicillin and 100 lg/mL streptomycin) antibiotics were added, followed by another incubation in 5% CO 2 at 37°C for different lengths of time. Viral supernatants and infected cell lysates and were collected and subjected to quantitative RT-PCR analyses aimed at the ORFIb region <ref type="bibr" target="#b11">[12]</ref>. Pseudotyped SARS-CoV particle quantities were determined in terms of luciferase activity. For neutralization assays, HL-CZ or Vero E6 cells were added to 96-well tissue culture plates (5 Â 10 4 cells/well). SARS-CoV (3.125 TCID 50 ) or SARS-CoV pseudotyped viruses (100 ng of p24) were mixed with various mAbs or sera at different dilutions and incubated at 37°C for 2 h before being added to HL-CZ or Vero E6 cells. Culture supernatants were collected 2-4 d post-infection; viral loads were measured by real-time RT-PCR.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.4.">Real-time RT-PCR</head><p>Viral RNA was extracted from culture supernatant using a QIAamp Viral RNA Mini Kit (Qiagen). The two real-time RT-PCR primer sets used to measure mRNAs were CDC-2 forward and reverse (nucleocapsid; U.S. CDC catalogue #KT0051) <ref type="bibr" target="#b10">[11]</ref> and BNIoutS and BNIoutAS (ORF Ib) <ref type="bibr" target="#b11">[12]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.5.">Flow cytometry and immunofluorescence staining</head><p>Cells were harvested and held for 30 min at 4°C in PBS containing 1% FBS, followed by another 30 min of incubation at 4°C with isotype-matched control or monoclonal antibodies (1 lg/ml) for each indicated human Fc receptor. Immunofluorescence staining procedures are described in <ref type="bibr" target="#b12">[13]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.6.">SARS-CoV S and N protein preparation</head><p>A Taiwanese SARS-CoV isolate TW1 strain (GenBank accession No. AY291451) was used as a template to clone and amplify nucleocapsid and spike genes using plasmids expressed in the prokaryote system. Details and schemes are described in the Supplemental file; see especially S-Figs. 2 and 3 <ref type="bibr" target="#b2">[3,</ref><ref type="bibr" target="#b10">11]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.7.">Generation of monoclonal or polyclonal antibodies against SARS-CoV S and N proteins</head><p>Our procedures for generating monoclonal or polyclonal antibodies are the same as those described in <ref type="bibr" target="#b13">[14]</ref>. Briefly, BALB/c mice were immunized once and given two boosters of 25 lg GST-spike (GST-SIa, -SIb, and -SII) recombinant proteins in 0.25 ml of PBS emulsified with equal volumes of complete/incomplete Freund's adjuvant (Sigma-Aldrich, St. Louis, MO). ELISAs and Western blots were used to confirm antibody titers against these recombinant fusion proteins prior to harvesting splenocytes and fusing them with NS-1 myeloma cells. ELISAs and Western blots were also used to screen hybridoma culture supernatants for the GST-spike fusion protein. Clones producing specific antibodies were selected using the dilution method described in <ref type="bibr" target="#b14">[15]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.8.">Apoptosis assays</head><p>HL-CZ cell apoptosis assays were performed using Annexin V staining.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.9.">Immunoblotting</head><p>HL-CZ or Vero-E6 cells were infected with SARS-CoV and incubated at 37°C for 48-72 h. Culture supernatants were concentrated by ultracentrifugation at 25,000 rpm for 2.5 h and lysed in SDS-PAGE sample buffer. SDS-PAGE electrophoresis was performed according to the protocols given in <ref type="bibr" target="#b10">[11,</ref><ref type="bibr" target="#b13">14]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.10.">Antibody-dependent enhancement assays</head><p>Assay details are as previously described <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b15">16,</ref><ref type="bibr" target="#b16">17]</ref>. Assays were performed using sera from normal and SARS-CoV-positive patients. Rabbit polyclonal or mouse monoclonal antibodies against S or N proteins were used to evaluate ADE. HL-CZ cells were infected with SARS-CoV or pseudotyped viruses in the presence of control and either anti-spike or anti-nucleocapsid antibodies (10-to 2000-fold dilution) and incubated at 37°C for 48 h. Supernatants and cell lysates were collected and viral titers determined by quantitative RT-PCR or luminescence analyses.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.11.">Statistical analyses</head><p>All experiments were performed a minimum of three times. GraphPad Prism software was used for all statistical analyses. Statistical significance (p &lt; 0.05) was calculated using unpaired Student's t-tests.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.">Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.1.">Susceptibility of HL-CZ cells to SARS-CoV infection</head><p>Previous researchers have infected HL-CZ human promonocyte cells with HIV-1 and dengue viruses, among several others <ref type="bibr" target="#b8">[9]</ref>. Our infectivity assay results indicate that HL-CZ can be infected by SARS-CoV <ref type="figure" target="#fig_0">(Fig. 1A)</ref>. According to quantitative RT-PCR data, higher mRNA expression levels of TNF-a, IL-4 and IL-6 were detected in HL-CZ cells 2 d post-infection <ref type="figure" target="#fig_0">(Fig. 1B)</ref>. Trace levels of IL-3 and IL-1b were also detected (data not shown). Light microscopy and immunofluorescence staining observations indicate (a) a cytopathic effect (CPE) 2 d post-infection <ref type="figure" target="#fig_0">(Fig. 1C)</ref> and (b) the presence of SARS-CoV in SARS-CoV-infected HL-CZ cells, detected by antisera collected from SARS-CoV-positive patients <ref type="figure" target="#fig_0">(Fig. 1C)</ref>. Infectious SARS-CoV virus production in HL-CZ cells was confirmed by using supernatants from those cells to infect Vero-E6 cells, which are known to be susceptible to coronaviruses. We also observed a significant CPE in Vero-E6 cells on days 2 and 4 post-infection <ref type="figure" target="#fig_0">(Fig. 1D</ref>).</p><p>3.2. HL-CZ cells express angiotensin-converting enzyme 2 (ACE 2) and Fcc receptors, and display antibody-dependent SARS-CoV infectivity ACE2 is a functional SARS-CoV receptor that is abundant in human lung and small intestine epithelial cells <ref type="bibr" target="#b17">[18]</ref>. Fc receptors (FcR) and complement receptors <ref type="bibr" target="#b6">[7]</ref>, which have been identified as alternatives for the cellular entry of certain viruses, have been shown to enhance antibody-dependent infectivity <ref type="bibr" target="#b6">[7,</ref><ref type="bibr" target="#b16">17]</ref>. Our flow cytometry results indicate that the HL-CZ cells expressed both ACE2 receptors and higher levels of FcRII (CD32) <ref type="figure" target="#fig_1">(Fig. 2A)</ref>.</p><p>We tried to determine if this antibody-dependent enhancement also occurred in SARS-CoV-infected HL-CZ cells. Our data indicate that treatment with anti-sera collected from SARS-CoV patients and diluted 1000-to 2000-fold resulted in increased virus infectivity and CPE compared to treatment with 10-fold diluted anti-sera <ref type="figure" target="#fig_1">(Fig. 2B</ref>). According to transmission electron microscopy images, higher quantities of SARS-CoV viral particles were observed in HL-CZ cells treated with more diluted anti-sera against SARS-CoV (2000-fold dilution) <ref type="figure" target="#fig_1">(Fig. 2C-3</ref>) compared to those treated with less diluted anti-sera (10-fold) <ref type="figure" target="#fig_0">(Fig. 2C-1</ref>) and less diluted normal control sera (10-fold) <ref type="figure" target="#fig_1">(Fig. 2C-2)</ref>. We performed additional infectivity assays to confirm this observation, and found significantly higher levels of virus infection following treatment with 100-and 1000-fold diluted anti-sera compared to control sera from non-SARS-CoV patients at the same dilutions (p &lt; 0.05) <ref type="figure" target="#fig_2">(Fig. 3A)</ref>. We also found that highly diluted anti-sera against SARS-CoV significantly increased virus-induced apoptosis in HL-CZ cells compared to normal sera at the same dilutions (p &lt; 0.05) <ref type="figure" target="#fig_2">(Fig. 3B</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.3.">Antibody-dependent SARS-CoV enhancement is mediated by antispike antibodies</head><p>Our next task was to determine which antibody promoted SARS-CoV infection. We noted that antibodies against S and N proteins were produced at high levels during SARS-CoV infections, and therefore used S-and N-protein-recognizing antibodies to detect early SARS-CoV infections. After generating mouse antibodies against S and N recombinant proteins (Supplemental <ref type="figure" target="#fig_0">Figs. 1-3)</ref>, we performed infectivity assays using different mouse sera against S or N proteins at different dilutions. Assay results indicate that diluted anti-S mouse sera exhibited significantly greater SARS-CoV ADE effects on HL-CZ cells compared to diluted mouse control sera (p &lt; 0.05) <ref type="figure" target="#fig_2">(Fig. 3C)</ref>. Note that diluted anti-N mouse sera did not exert any SARS-CoV ADE effects on HL-CZ cells <ref type="figure" target="#fig_2">(Fig. 3D)</ref>.</p><p>A series of monoclonal antibodies (mAbs) against spike proteins was generated to confirm this finding (Supplemental <ref type="figure" target="#fig_0">Figs. 1 and 3</ref>). S-protein epitopes recognized by the mAbs are shown in <ref type="figure" target="#fig_3">Fig. 4A</ref>. As shown, only SIb4 (epitope 435 NYNWKR 440 in the SIb region) had neutralizing capabilities. Other monoclonal antibodies against S proteins exhibited mild-to-moderate enhancement effects on lentiviral particles carrying a luciferase gene pseudotyped with SARS envelope spike proteins <ref type="figure" target="#fig_3">(Fig. 4B)</ref>. Infectivity assay results also indicate that the SIb4 mAb significantly inhibited the SARS-CoV infection of HL-CZ cells, while SIb2 promoted virus infection compared to the isotype control. According to microscopy observations, SIb2 promoted a significantly stronger CPE compared to SIb4 (which also displayed neutralizing capability) and the isotypic control <ref type="figure" target="#fig_3">(Fig. 4D</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.">Discussion</head><p>While the generation of protective antibodies against specific proteins is a useful strategy for microbial disease control, some immune responses to pathogens can have deleterious effectsfor example, cytokine storms associated with avian influenza virus, and increased mortality from SARS-CoV infections. Cell infection via antibody-dependent enhancement has been observed for several viral diseases, including dengue virus, HIV-1, and feline infectious peritonitis virus (FIPV) <ref type="bibr" target="#b6">[7,</ref><ref type="bibr" target="#b12">13]</ref>. In the present study we identified the susceptibility of an alternative cell line, HL-CZ, to SARS-CoV infection <ref type="figure" target="#fig_0">(Fig. 1)</ref>. Specifically, we found that HL-CZ cells express ACE2 receptors and display a cytopathic effect induced by SARS-CoV. Two research teams have reported that ACE2 serves as a functional receptor for SARS-CoV infection, and that human peripheral monocytes and macrophages can be infected by SARS-CoV <ref type="bibr" target="#b18">[19,</ref><ref type="bibr" target="#b19">20]</ref>. Our results suggest that HL-CZ can serve as an alternative cell line for SARS-CoV research-specifically, SARS-CoV-infected HL-CZ cells showed increased TNF-a, IL-4, and IL-6 secretions <ref type="figure" target="#fig_0">(Fig. 1B)</ref>, but only trace amounts of IL-3 and IL-1b. According to the same two studies, human peripheral monocytes and macrophages can be infected by SARS-CoV. Another research group observed the up-regulation of IL-6 and TNF-a induced by the SARS-CoV spike protein in murine macrophages, and identified IL-6 and IL-8 as key SARS-CoV-induced epithelial cytokines <ref type="bibr" target="#b20">[21]</ref>. Combined, these data suggest that SARS-CoV-induced IL-6 and TNF-a play roles in SARS pathogenesis, especially in terms of inflammation and high fever.</p><p>Currently there are no licensed vaccines against human coronaviruses. For animals, vaccines have been generated against several, including the transmissible gastroenteritis virus <ref type="bibr" target="#b21">[22]</ref>. However, attempts to develop a feline coronavirus vaccine have failed due to ADE <ref type="bibr" target="#b7">[8]</ref>, which is mediated by receptors-most notably the Fc gamma receptor (FccR), which facilitates antigenantibody complex uptake by target cells. Our data indicate that HL-CZ cells express high levels of FccRII. According to one report, FccRII (CD32) plays a predominant role in mediating of SARS-CoV by using antibodies against different types of FccRs on immune cells <ref type="bibr" target="#b16">[17]</ref>. In that study, THP-1, Raji, and Daudi cells displayed ADE during SARS-CoV infection <ref type="bibr" target="#b16">[17]</ref>. We found that FcyRII and ACE2 receptors were expressed in THP-1, Raji, and HL-CZ cells (Supplemental <ref type="figure" target="#fig_3">Fig. 4)</ref>. Combined, these findings suggest that FcyRII is important for ADE mediation in some types of immune cells during SARS-CoV infection. Some antibodies are capable of increasing virus replication efficiency by either boosting the uptake of infectious antibody-virus complexes, or by increasing the synthesis of viral proteins and nucleic acid <ref type="bibr" target="#b22">[23]</ref>. There has been at least one report indicating that compared to untreated viruses, HIV-1 replication speeds up when viruses are pretreated with HIV-1 antibodies <ref type="bibr" target="#b23">[24]</ref>. According to another report, a higher FIPV infection rate in macrophages occurred when anti-FIPV antibodies were present <ref type="bibr" target="#b24">[25]</ref>.</p><p>We found that higher concentrations of anti-sera collected from SARS-CoV-infected patients (10-to 100-fold dilution) displayed greater viral neutralization capability compared to more diluted concentrations (1000-to 2000-fold), which facilitated SARS-CoV infection and induced higher levels of virus-induced apoptosis <ref type="figure" target="#fig_2">(Fig. 3)</ref>. We found that this phenomenon occurred via ADE and was mediated by anti-S antibodies, but not by anti-N antibodies. At least two studies have shown that SARS-CoV infection induces abundant amounts of antibodies against S and N proteins <ref type="bibr" target="#b1">[2,</ref><ref type="bibr" target="#b5">6]</ref>. Spike proteins, especially those in the ACE-2 binding region (318-510 aa), are capable of producing SARS-CoV-neutralizing antibodies; nucleocapsid proteins induce cytotoxic T lymphocyte (CTL) immune responses that are specifically SARS-CoV-protective <ref type="bibr" target="#b25">[26]</ref>. However, another research team has suggested that SARS-CoV subunit vaccines may induce neutralization and/or partial ADE effects via B lineage cells <ref type="bibr" target="#b15">[16]</ref>. In a separate report describing similar results, the researchers suggested that vaccine-induced anti-spike antibodies against trimeric S proteins may mediate the ADE of SARS-CoV-pseudotyped virus entry into FcR-expressing cells <ref type="bibr" target="#b26">[27]</ref>. Our anti-spike monoclonal antibody data indicate that most of those against SIa regions (1-460 aa) displayed the ADE effect on both SARS-CoV-pseudotyped <ref type="figure" target="#fig_3">(Fig. 4B</ref>) and real viruses <ref type="figure" target="#fig_3">(Fig. 4C)</ref>, and that only one monoclonal antibody against Slb regions (416-486 aa) showed viral neutralizing capability. The associated mechanisms require further investigation.</p><p>In this study we identified an alternative susceptible cell line, HL-CZ, for future SARS-CoV research, and found that ADE associated with SARS-CoV infection is primarily mediated by anti-spike antibodies. It is our hope that this information will be useful in the development of a human SARS-CoV vaccine, as well as in research involving immune-mediated infections tied to SARS pathogenesis. </p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 1 .</head><label>1</label><figDesc>HL-CZ cells are susceptible to SARS-CoV infection. After infecting cells with SARS-CoV, culture supernatant and cell lysates were collected for (A) SARS-CoV detection and (B) cellular cytokine mRNA expression. (C) Results from HL-CZ cytopathic effect observation and immunofluorescence staining 2 d post-infection. (D) Supernatants from mock and SARS-CoV-infected HL-CZ cells were used to infect Vero-E6 cells for 2 d. Results are from one representative experiment of the three performed.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig. 2 .</head><label>2</label><figDesc>HL-CZ cells express ACE2 and Fc receptors, and display antibody-dependent enhancement. (A) Results from flow cytometry analyses of Fc receptors and ACE2 expression in HL-CZ cells. (B) SARS-CoV or mock infections in the presence of various dilutions of anti-sera drawn from SARS-CoV patients. (C) Transmission electron microscopy images of HL-CZ cells infected with SARS-CoV in the presence of various dilutions of anti-sera against SARS-CoV. Images 1 and 3 indicate 10-, and 2000-fold dilutions of anti-sera against SARS-CoV, respectively. Image 2 indicates 10-fold dilutions of normal sera control treatment.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Fig. 3 .</head><label>3</label><figDesc>Antibody-dependent enhancement of SARS-CoV infection is mediated by anti-spike protein antibodies. (A) Results from infectivity assays using HL-CZ cells infected with SARS-CoV and treated with various dilutions of anti-sera collected from SARS-CoV patients. (B) Apoptosis analyses of HL-CZ cells infected with SARS-CoV in the presence of 1000-fold diluted normal sera and anti-SARS-CoV sera (Annexin V staining). (C) HL-CZ cells infected with SARS-CoV in the presence of various dilutions (10-, 100-, 1000-or 2000-fold) of mouse anti-spike protein serum and isotype control mouse serum. (D) HL-CZ cells infected with SARS-CoV in the presence of different dilutions (10-, 100-, 1000or 2000-fold) of mouse anti-nucleocapsid serum and isotype control mouse serum. C, normal sera (control); S, anti-SARS sera (sample). Shown are results from one representative experiment of three performed ( ⁄ p &lt; 0.05; ⁄⁄ p &lt; 0.01).</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Fig. 4 .</head><label>4</label><figDesc>Monoclonal antibodies against the SIa regions of spike proteins show antibody-dependent enhancement capability. (A) Isotype and epitope mapping of monoclonal antibodies against SARS-CoV spike proteins (NI ⁄ , not identified; bold, conservative amino acid residues). Lower part, fragment scheme of spike proteins used to generate monoclonal antibodies. (B) Evaluations of ADE effects of SARS-CoV-pseudotyped virus infections of HL-CZ cells in the presence of the monoclonal antibodies listed in (A). (C) Infectivity assays were performed using SARS-CoV-infected HL-CZ cells treated with SIb4, SIb2, or isotype control antibodies. (D) Cytopathic effects observed in HL-CZ cells treated with SIb4, SIb2, or isotype control antibodies. Presented results are from one representative experiment of three performed ( ⁄ p &lt; 0.05; ⁄⁄ p &lt; 0.01).</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0" validated="false"><head></head><label></label><figDesc>and ORF1b, which http://dx.doi.org/10.1016/j.bbrc.2014.07.090 0006-291X/Ó 2014 Elsevier Inc. All rights reserved.</figDesc><table></table></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgments</head><p>The authors wish to thank their colleagues at the AIDS Prevention and Research Center of National Yang-Ming University and the Center of Infectious Disease and Cancer Research of Kaohsiung Medical University for their assistance and useful discussions. This research was supported by Grants from the National Science Council, Republic of China (NSC 101-2320-B-010-055-MY3).</p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Appendix A. Supplementary data</head><p>Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.bbrc.2014.07.090.</p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
				<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">R</forename><surname>Hsueh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">C</forename><surname>Yang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">SARS outbreak in Taiwan</title>
		<imprint>
			<date type="published" when="2004" />
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="1515" to="1516" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Antibody detection of SARS-CoV spike and nucleocapsid protein</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">S</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">T</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">T</forename><surname>Ho</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">C</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">Y</forename><surname>Wei</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">J</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">T</forename><surname>Hsu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">C</forename><surname>Chu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">H</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Chu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">L</forename><surname>Jan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">C</forename><surname>Hung</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">C</forename><surname>Fan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">C</forename><surname>Yang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochem. Biophys. Res. Commun</title>
		<imprint>
			<biblScope unit="volume">314</biblScope>
			<biblScope unit="page" from="931" to="936" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Epidemiological and genetic correlates of severe acute respiratory syndrome coronavirus infection in the hospital with the highest nosocomial infection rate in Taiwan in 2003</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">M</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">Y</forename><surname>Liang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">P</forename><surname>Shih</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">Y</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">M</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">Y</forename><surname>Jung</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">S</forename><surname>Ho</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">Y</forename><surname>Liang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">Y</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">J</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">C</forename><surname>Chu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Clin. Microbiol</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="359" to="365" />
			<date type="published" when="2006" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Angiotensinconverting enzyme 2 is a functional receptor for the SARS coronavirus</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">J</forename><surname>Moore</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Vasilieva</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Sui</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">K</forename><surname>Wong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">A</forename><surname>Berne</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Somasundaran</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">L</forename><surname>Sullivan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Luzuriaga</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">C</forename><surname>Greenough</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Choe</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Farzan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">426</biblScope>
			<biblScope unit="page" from="450" to="454" />
			<date type="published" when="2003" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Antibody-mediated protection against mucosal simianhuman immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">W</forename><surname>Barnett</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Burke</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Kan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Legg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Lian</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Bost</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Goodsell</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Zur Megede</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Polo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Donnelly</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Ulmer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">R</forename><surname>Otten</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">J</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Vajdy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><forename type="middle">K</forename><surname>Srivastava</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Virol</title>
		<imprint>
			<biblScope unit="volume">84</biblScope>
			<biblScope unit="page" from="5975" to="5985" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Antigenicity analysis of different regions of the severe acute respiratory syndrome coronavirus nucleocapsid protein</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Z</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Pei</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Zhai</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Z</forename><surname>Du</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Qiu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Han</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Z</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Yang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin. Chem</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="page" from="988" to="995" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Antibody-dependent enhancement of virus infection and disease</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">M</forename><surname>Tirado</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">J</forename><surname>Yoon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Viral Immunol</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="69" to="86" />
			<date type="published" when="2003" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Monoclonal antibodies to the spike protein of feline infectious peritonitis virus mediate antibody-dependent enhancement of infection of feline macrophages</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">W</forename><surname>Olsen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">V</forename><surname>Corapi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">K</forename><surname>Ngichabe</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">D</forename><surname>Baines</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><forename type="middle">W</forename><surname>Scott</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Virol</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="956" to="965" />
			<date type="published" when="1992" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Isolation of dengue virus with a human promonocyte cell line</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">T</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">L</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">S</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">C</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><forename type="middle">L</forename><surname>Lo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">C</forename><surname>Ko</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am. J. Trop. Med. Hyg</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="494" to="499" />
			<date type="published" when="1991" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Microbiologic characteristics, serologic responses, and clinical manifestations in severe acute respiratory syndrome</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">R</forename><surname>Hsueh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">H</forename><surname>Hsiao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">H</forename><surname>Yeh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">K</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">J</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">T</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">C</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">L</forename><surname>Kao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">C</forename><surname>Yang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Infect. Dis</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="1163" to="1167" />
			<date type="published" when="2003" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Identifying epitopes responsible for neutralizing antibody and DC-SIGN binding on the spike glycoprotein of the severe acute respiratory syndrome coronavirus</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">P</forename><surname>Shih</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">Y</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">J</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">H</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">M</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">C</forename><surname>Chao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">M</forename><surname>Chen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Virol</title>
		<imprint>
			<biblScope unit="volume">80</biblScope>
			<biblScope unit="page" from="10315" to="10324" />
			<date type="published" when="2006" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Sensitive and quantitative detection of severe acute respiratory syndrome coronavirus infection by real-time nested polymerase chain reaction</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">S</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">C</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">Y</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">A</forename><surname>Hsiung</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><forename type="middle">J</forename><surname>Su</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">L</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">C</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">L</forename><surname>Juang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin. Infect. Dis</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="293" to="296" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">DC-SIGN mediates avian H5N1 influenza virus infection in cis and in trans</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">F</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">C</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">M</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">J</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">J</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">P</forename><surname>Chau</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Chong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">M</forename><surname>Chen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochem. Biophys. Res. Commun</title>
		<imprint>
			<biblScope unit="volume">373</biblScope>
			<biblScope unit="page" from="561" to="566" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Generating and characterizing monoclonal and polyclonal antibodies against avian H5N1 hemagglutinin protein</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">F</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">H</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Thitithanyanont</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Yao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">M</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">J</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">J</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Chong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">T</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">C</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">M</forename><surname>Chen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochem. Biophys. Res. Commun</title>
		<imprint>
			<biblScope unit="volume">382</biblScope>
			<biblScope unit="page" from="691" to="696" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Detection of circulating Asian H5N1 viruses by a newly established monoclonal antibody</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Du</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Daidoji</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Koma</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">S</forename><surname>Ibrahim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Nakamura</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">U</forename><forename type="middle">C</forename><surname>Silva</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Ueda</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">S</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Yasunaga</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Ikuta</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Nakaya</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochem. Biophys. Res. Commun</title>
		<imprint>
			<biblScope unit="volume">378</biblScope>
			<biblScope unit="page" from="197" to="202" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">SARS CoV subunit vaccine: antibody-mediated neutralisation and enhancement</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Jaume</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">S</forename><surname>Yip</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">W</forename><surname>Kam</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">Y</forename><surname>Cheung</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Kien</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Roberts</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">H</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Dutry</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Escriou</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Daeron</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Bruzzone</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Subbarao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">S</forename><surname>Peiris</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Nal</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Altmeyer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hong Kong Med. J</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="31" to="36" />
			<date type="published" when="2012" />
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH-and cysteine protease-independent FcgammaR pathway</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Jaume</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">S</forename><surname>Yip</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">Y</forename><surname>Cheung</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">L</forename><surname>Leung</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">H</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Kien</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Dutry</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Callendret</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Escriou</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Altmeyer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Nal</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Daeron</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Bruzzone</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">S</forename><surname>Peiris</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Virol</title>
		<imprint>
			<biblScope unit="volume">85</biblScope>
			<biblScope unit="page" from="10582" to="10597" />
			<date type="published" when="2011" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Hamming</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><surname>Timens</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">L</forename><surname>Bulthuis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">T</forename><surname>Lely</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Navis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Van Goor</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Pathol</title>
		<imprint>
			<biblScope unit="volume">203</biblScope>
			<biblScope unit="page" from="631" to="637" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">SARS-coronavirus replication in human peripheral monocytes/macrophages</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Yilla</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">H</forename><surname>Harcourt</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">J</forename><surname>Hickman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Mcgrew</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Tamin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">S</forename><surname>Goldsmith</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">J</forename><surname>Bellini</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">J</forename><surname>Anderson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Virus Res</title>
		<imprint>
			<biblScope unit="volume">107</biblScope>
			<biblScope unit="page" from="93" to="101" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Upregulation of IL-6 and TNF-alpha induced by SARS-coronavirus spike protein in murine macrophages via NF-kappaB pathway</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Ye</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Zeng</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Kong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">X</forename><surname>Fang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Z</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>She</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Virus Res</title>
		<imprint>
			<biblScope unit="volume">128</biblScope>
			<biblScope unit="page" from="1" to="8" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Severe acute respiratory syndrome (SARS) coronavirus-induced lung epithelial cytokines exacerbate SARS pathogenesis by modulating intrinsic functions of monocyte-derived macrophages and dendritic cells</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Yoshikawa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Hill</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">J</forename><surname>Peters</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">T</forename><surname>Tseng</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Virol</title>
		<imprint>
			<biblScope unit="volume">83</biblScope>
			<biblScope unit="page" from="3039" to="3048" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Immune response of sows vaccinated with attenuated transmissible gastroenteritis virus (TGEV) and recombinant TGEV spike protein vaccines and protection of their suckling pigs against virulent TGEV challenge exposure</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Sestak</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">C</forename><surname>Hodgins</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">I</forename><surname>Shoup</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">A</forename><surname>Ward</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">J</forename><surname>Jackwood</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">J</forename><surname>Saif</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am. J. Vet. Res</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="1002" to="1008" />
			<date type="published" when="1998" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Flavivirus infection enhancement in macrophages: radioactive and biological studies on the effect of antibody on viral fate</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">W</forename><surname>Gollins</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">S</forename><surname>Porterfield</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Gen. Virol</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1261" to="1272" />
			<date type="published" when="1984" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Complementmediated, antibody-dependent enhancement of HIV-1 infection in vitro is characterized by increased protein and RNA syntheses and infectious virus release</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">E</forename><surname>Robinson</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">C</forename><surname>Montefiori</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">H</forename><surname>Gillespie</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">M</forename><surname>Mitchell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Acquir. Immune Defic. Syndr</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="33" to="42" />
			<date type="published" when="1989" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Evaluation of antibody-dependent enhancement of feline infectious peritonitis virus infectivity using in situ hybridization</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Olsen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Scott</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Microb. Pathog</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="275" to="285" />
			<date type="published" when="1993" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
				<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Zhu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">SARS immunity and vaccination</title>
		<imprint>
			<date type="published" when="2004" />
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="193" to="198" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">W</forename><surname>Kam</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Kien</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Roberts</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">C</forename><surname>Cheung</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">W</forename><surname>Lamirande</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Vogel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">L</forename><surname>Chu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Tse</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Guarner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">R</forename><surname>Zaki</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Subbarao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Peiris</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Nal</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Altmeyer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Vaccine</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="729" to="740" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
